Yahoo Web Search

Search results

1. • Johnson & Johnson (NYSE:JNJ) Trading Down 1.1%

     ETF DAILY NEWS· 16 hours ago

     Shares of Johnson & Johnson (NYSE:JNJ – Get Free Report) were down 1.1% during mid-day trading on Thursday . The company traded as low as $151.70 and last traded at $151.81. Approximately 1,428,737 ...

2. • 

     Guselkumab Continues Winning Streak in Crohn's Disease

     MedPage Today· 4 days ago

     Induction and maintenance treatment with guselkumab (Tremfya) demonstrated its safety and efficacy...

3. • 

     Potential Precursor Lesion to Adrenal Tumors Identified

     Medscape· 3 days ago

     Cortisol-producing adenomas (CPAs) are preceded by the development of steroids-producing nodules...

4. • 

     Maintenance Tx With Guselkumab for UC Meets All Endpoints

     Medscape· 4 days ago

     Guselkumab (Tremfya, Janssen/Johnson & Johnson) was superior to placebo for maintenance therapy in...

5. • Tracking down the genetic causes of lupus to personalize treatment

     Medical Xpress· 2 days ago

     Researchers are just now beginning to link specific genetic mutations to subsets of lupus patients, allowing physicians to target therapies to those who will benefit most. In the latest advance ...

6. • Tracking down the genetic causes of lupus to personalize treatment

     Science Daily· 3 days ago

     Researchers are just now beginning to link specific genetic mutations to subsets of lupus patients, allowing physicians to target therapies to those who will benefit most. In the latest advance ...

7. • Johnson & Johnson (NYSE:JNJ) Stock Rating Reaffirmed by Royal Bank of Canada

     ETF DAILY NEWS· 2 days ago

     Johnson & Johnson (NYSE:JNJ – Get Free Report)‘s stock had its “outperform” rating reiterated by research analysts at Royal Bank of Canada in a report issued on Wednesday, Benzinga reports.

8. • Windle Wealth LLC Purchases 1,266 Shares of Johnson & Johnson (NYSE:JNJ)

     ETF DAILY NEWS· 4 days ago

     Windle Wealth LLC grew its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 3.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange ...

9. • AbbVie (NYSE:ABBV) vs. Cosmo Pharmaceuticals (OTC:CMOPF) Head to Head Review

     ETF DAILY NEWS· 23 hours ago

     AbbVie (NYSE:ABBV – Get Free Report) and Cosmo Pharmaceuticals (OTC:CMOPF – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses ...

10. • Johnson & Johnson (NYSE:JNJ) Shares Bought by BI Asset Management Fondsmaeglerselskab A S

      ETF DAILY NEWS· 5 days ago

      BI Asset Management Fondsmaeglerselskab A S lifted its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 59.0% in the 4th quarter, according to the company in its most recent 13F filing ...